COMMUNIQUÉS West-GlobeNewswire

Intelligent Bio Solutions to Present at the LD Micro Invitational XIV Investor Conference on April 9 in NYC
26/03/2024
NEW YORK, March 26, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today [...]
Yield10 Bioscience Announces that the Plant Biosafety Office of the Canadian Food Inspection Agency has Cleared Genome-edited E3902 Camelina for Planting in Canada
26/03/2024
WOBURN, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today reported that the Plant Biosafety Office (“PBO”) of the [...]
Surgery Partners, Inc. Announces New Senior Notes Offering
26/03/2024
BRENTWOOD, Tenn., March 26, 2024 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, announced today that Surgery [...]
Essential Pharma and AcedrA Biopharmaceuticals sign Distribution Agreement to commercialize essential medicines in the Middle East and North Africa region
26/03/2024
ZUG, Switzerland and EGHAM, United Kingdom and RIYADH, Saudi Arabia, March 26, 2024 (GLOBE NEWSWIRE) -- Essential Pharma, an international specialty pharma group focused on ensuring that patients have sustainable access [...]
Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results
26/03/2024
U.S. IND filed for THB335 with anticipated clinical trial start during 2Q’24 Strong financial position with cash and cash equivalents totaling $269.1 million as of December 31, 2023 SAN FRANCISCO, March 26, 2024 (GLOBE [...]
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares
26/03/2024
Company generated approximately $2.8M of non-dilutive funding to extend cash runway WESTPORT, Conn., March 26, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company [...]
Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
26/03/2024
National TV and digital media campaign aims to motivate millions of people suffering from Erosive GERD to learn more about VOQUEZNA® (vonoprazan), the first and only FDA-approved potassium-competitive acid blocker (PCAB [...]
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
26/03/2024
MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sale of AL102, and [...]
Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors
26/03/2024
David Pacitti is currently the President of Siemens Medical Solutions USA, Inc. and Head of the Americas, Siemens Healthineers; formerly Division Vice President of U.S. Commercial Operations, Sales, and Marketing at [...]
Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update
26/03/2024
BETHESDA, Md., March 26, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of [...]
Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting
26/03/2024
CUPERTINO, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet [...]
Healis Therapeutics announces collaboration with Massachusetts General Hospital (MGH) and affiliates of Harvard Medical School to advance clinical-stage neuroscience research
26/03/2024
NEWPORT BEACH, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Healis Therapeutics is pleased to announce that it has entered a clinical collaboration with Massachusetts General Hospital (MGH), a founding member of the Mass [...]
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
26/03/2024
NEW YORK, March 26, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the [...]
GTG Global Collaborations and Innovation Update
26/03/2024
MELBOURNE, Australia, March 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is [...]
Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024
26/03/2024
FOSTER CITY, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today [...]
Opus Genetics Announces Completion of Dosing in First Cohort of Phase 1/2 Trial of Gene Therapy OPGx-LCA5 in Patients with Rare Inherited Retinal Disease LCA5
26/03/2024
OPGx-LCA5 will advance to the next highest dose in mid-2024 based on positive safety and efficacy data OPGx-LCA5 is well-tolerated and demonstrated clear signs of biological activity RESEARCH TRIANGLE PARK, N.C., March [...]
American Oncology Network Expands Footprint in Texas with the Addition of Woodlands Cancer Institute in Houston
26/03/2024
Woodlands Cancer Institute opens three clinic locations that provide medical oncology, radiation oncology and hematology care to its patients. WOODLANDS, Texas, March 26, 2024 (GLOBE NEWSWIRE) -- American Oncology [...]
HealthLynked Announces Exciting New Update with HealthLynked 3.2.0 - Transforming Patient-Care Through Innovation
26/03/2024
NAPLES, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- via IBN – HealthLynked Corp. (OTCQB: HLYK), a pioneering healthcare network focused on enhancing the efficiency and quality of patient care, is thrilled to announce the [...]
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
26/03/2024
First-in-class macrocyclic ATR inhibitor, ATRN-119, on track to complete dose escalation and potentially generate human efficacy data in H2 2024 U.S. FDA cleared IND for APR-1051, a highly selective and potentially best [...]

Pages